Knowledge sources, patent protection, and commercialization of pharmaceutical innovations

Research Policy

Volumn 39, Issue 6, 2010, Pages 810-821

  Sternitzke, Christian ^a,b,c  

^a ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c CFH Beteiligungsgesellschaft   (Germany)

Author keywords

Drug lifecycle management; Patents; Radical innovations; Technological trajectories; Time lags

Indexed keywords

INNOVATION;

BIBLIOMETRIC INDICATORS; LIFE-CYCLE MANAGEMENT; PATENTS; PHARMACEUTICAL INDUSTRY; PHARMACEUTICAL INNOVATIONS; RADICAL INNOVATION; TIME LAG; UNITED STATES FOOD AND DRUG ADMINISTRATIONS;

PATENTS AND INVENTIONS;

EID: 78049480168     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2010.03.001     Document Type: Article

References (75)

1. Achilladelis, B., 1993. The dynamics of technological innovation: The sector of antibacterial medicines. Research Policy 22 (4), 279-303.
2. Achilladelis, B., Antonakis, N., 2001. The dynamics of technological innovation: The case of the pharmaceutical industry. Research Policy 30 (4), 535-588. (Pubitemid 33675445)
3. Achilladelis, B., Schwarzkopf, A., Cines, M., 1990. The dynamics of technological innovation: The case of the chemical industry. Research Policy 19 (1), 1-34.
4. Andersen, B., 1999. The hunt for S-shaped growth paths in technological innovation: A patent study. Journal of Evolutionary Economics 9 (4), 487-526.
5. Arundel, A., Kabla, I., 1998. What percentage of innovations are patented?: Empirical estimates for European firms. Research Policy 27 (2), 127-141. (Pubitemid 128431009)
6. Ayres, R.U., 1988. Barriers and breakthroughs: An "expanding frontiers" model of the technology-industry life cycle. Technovation 7, 87-115.
7. Baum, J.R., Wally, S., 2003. Strategic decision speed and firm performance. Strategic Management Journal 24 (11), 1107-1129.
8. BPI, 2004. Pharma-Daten 2004. Bundesverband der Pharmazeutischen Industrie e.V. (BPI), http://www.bpi.de/UserFiles/File/bpi/publikationen/ pharmadaten 2004.pdf (19.04.07).
9. Chandy, R.K., Tellis, G.J., 1998. Organizing for radical product innovation: The overlooked role of willingness to cannibalize. Journal of Marketing Research 35 (4), 474-487.
10. Chandy, R., Hopstaken, B., Narasimhan, O., Prabhu, J., 2006. From invention to innovation: Conversion ability in product development. Journal of Marketing Research 43 (3), 494-508. (Pubitemid 44367345)
11. Chaney, P.K., Devinney, T.M., Winer, R.S., 1991. The impact of new product introductions on the market value of firms. The Journal of Business 64 (4), 573-610.
12. Chong, C.R., Sullivan Jr., D.J., 2007. New uses for old drugs. Nature 448 (9 August), 645-646. (Pubitemid 47236844)
13. Christensen, C.M., 1997. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail. The Management of Innovation and Change Series. Harvard Business School Press, Boston, MA.
14. Cockburn, I.M., Henderson, R.M., 1998. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. The Journal of Industrial Economics 46 (2), 157-182.
15. Cockburn, I., Henderson, R., 1996. Public-private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States of America 93 (23), 12725-12730. (Pubitemid 26382709)
16. Cohen, F.J., 2005. Macro trends in pharmaceutical innovation. Nature Reviews Drug Discovery 4 (1), 78-84. (Pubitemid 40109592)
17. Cohen, W.M., Levinthal, D.A., 1989. Innovation and learning: The two faces of R & D. The Economic Journal 99 (September=No. 397), 569-596.
18. Comanor, W.S., Scherer, F.M., 1969. Patent statistics as ameasure of technical change. The Journal of Political Economy 77 (3), 392-398.
19. De Carolis, D.M., 2003. Competencies and imitability in the pharmaceutical industry: An analysis of their relationship with firm performance. Journal of Management 29 (1), 27-50. (Pubitemid 36153444)
20. DeCarolis, D.M., Deeds, D.L., 1999. The impact of stocks and flows of organizational knowledge on firm performance: An empirical investigation of the biotechnology industry. Strategic Management Journal 20 (10), 953-968. (Pubitemid 129545631)
21. Desarbo, W.S., Di Benedetto, A.C., Song, M., Sinha, I., 2005. Revisiting the miles and snow strategic framework: Uncovering interrelationships between strategic types, capabilities, environmental uncertainty, and firm performance. Strategic Management Journal 26 (1), 47-74. (Pubitemid 40162623)
22. DiMasi, J.A., 2001. New drug development in the United States from 1963 to 1999. Clinical Pharmacology und Therapeutics 69 (5), 286-296. (Pubitemid 32477069)
23. Dosi, G., 1982. Technological paradigms and technological trajectories. Research Policy 11 (3), 147-162.
24. Dosi, G., 1988. Sources, procedures, and microeconomic effects of innovation. Journal of Economic Literature 26 (3), 1120-1171.
25. European Commission, 2003. Third European Report on Science & Technology Indicators. Towards a Knowledge-based Economy. Directorate-General for Research, Brussels.
26. Fama, E.F., 1970. Efficient capital markets: A review of theory and empirical work. Journal of Finance 25 (2), 383-417.
27. Fama, E.F., 1991. Efficient capital markets. Journal of Finance 46 (5), 1575-1617.
28. Francis, J., Pagach, D., Stephan, J., 1992. The stock market response to earnings announcements released during trading versus nontrading periods. Journal of Accounting Research 30 (2), 165-184.
29. Freeman, C., Soete, L., 1997. The Economics of Industrial Innovation. Routledge, London.
30. Gambardella, A., 1992. Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Research Policy 21 (5), 391-407.
31. Gambardella, A., 1995. Science and Innovation: The US Pharmaceutical Industry During the 1980s. Cambridge Univ. Press, Cambridge.
32. Godoe, H., 2000. Innovation regimes. R & D and radical innovations in telecommunications. Research Policy 29 (9), 1033-1046.
33. Grabowski, H.G., Vernon, J., 1990. A new look at the returns and risks to pharmaceutical R & D. Management Science 36 (7), 804-821.
34. Grabowski, H., Vernon, J., 1994. Innovation and structural change in pharmaceuticals and biotechnology. Industrial and Corporate Change 3 (2), 435-449.
35. Hall, B.H., Jaffe, A.B., Trajtenberg, M., 2004. Market value and patent citations. http://emlab.berkeley.edu/users/bhhall/papers/HallJaffeTrajtenberg RJEjan04. pdf (15.04.05).
36. Healey, F.H., 1978. Industry's need for basic research. Research Management 21 (6), 12.
37. Henderson, R., Cockburn, I., 1994. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal 15 (Special Issue), 63-84.
38. Henderson, R., Orsenigo, L., Pisano, G.P., 1999. The pharmaceutical industry and the revolution in molecular biology in Mowery D. In: Mowery, D.C., Nelson Richard, R. (Eds.), Sources of Industrial Leadership: Studies of Seven Industries. Cambridge University Press, Cambridge, pp. 267-312.
39. Hicks, D.M., Isard, P.A., Martin, B.R., 1996. A morphology of Japanese and European corporate research networks. Research Policy 25 (3), 359-378. (Pubitemid 126374871)
40. Hicks, D., 1995. Published papers, tacit competencies and corporate management of the public-private character of knowledge. Industrial and Corporate Change 4 (2), 401-424.
41. Hirschey, M., Richardson, V.J., 2004. Are scientific indicators of patent quality useful to investors? Journal of Empirical Finance 11 (1), 91-107. (Pubitemid 37527870)
42. Howard, L., 2007. Use of patents in drug lifecycle management. Journal of Generic Medicines 4 (3), 230-236.
43. Jaffe, A.B., Trajtenberg, M., Fogarty, M.S., 2000. The Meaning of Patent Citations: Report on the NBER/Case-western Reserve Survey of Patentees, NBER working paper series, NBER, Cambridge, MA.
44. Katzenstein, L., Grossman, E.B., 2001. Viagra (sildenafil citrate): The Remarkable Story of the Discovery and Launch. Medical Information Press.
45. Kiernan, C., 1991. Industrial Perspectives on Innovation and Interactions with Universities: Government-University-Industry-Research Roundtable. National Academy Press, Washington, DC.
46. Klavans, R., Deeds, D.L., 1997. Competence building in biotechnology start-ups: The role of scientific discovery, technical development, and absorptive capacity. In: Sanchez, R., Heene, A. (Eds.), Strategic Learning and Knowledge Management, The Strategic Management Series. Wiley, Chichester, pp. 103-120.
47. Koenig, M.E.D., 1983. A bibliometric analysis of pharmaceutical research. Research Policy 12 (1), 15-36.
48. Kondratev, N.D., 1926. Die langen Wellen der Konjunktur. Mohr, Tübingen.
49. Lang, L.H.P., Stulz, R.M., 1994. Tobin's q, corporate diversification, and firm performance. Journal of Political Economy 102 (6), 1248-1280.
50. Levin, R.C., Klevorick, A.K., Nelson, R.R., Winter, S.G., 1987. Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity 3, 783-831.
51. Mansfield, E., 1991. Academic research and industrial innovation. Research Policy 20 (1), 1-12.
52. Mansfield, E., 1998. Academic research and industrial innovation: An update of empirical findings. Research Policy 26 (7/8), 773-776. (Pubitemid 128394436)
53. Mathieu, M.P., 2005. Parexel's Pharmaceutical R & D Statistical Sourcebook 2006/2007. Parexel International Corp.
54. Narin, F., 1976. Evaluative Bibliometrics: The Use of Publication and Citation Analysis in the Evaluation of Scientific Activity. Computer Horizons/CHI Research, Cherry Hill, NJ.
55. Narin, F., Hamilton, K.S., Olivastro, D., 1997. The increasing linkage between U.S. technology and public science. Research Policy 26 (3), 317-330. (Pubitemid 127382138)
56. Narin, F., Pinski, G., Hofer Gee, H., 1976. Structure of biomedical literature. Journal of the American Society for Information Science 27 (1), 25-45.
57. Narin, F., Rozek, R.P., 1988. Bibliometric analysis of U.S. pharmaceutical industry research performance. Research Policy 17 (3), 139-154.
58. PhRMA, 2007. Drug discovery and development. http://www.phrma.org/files/ attachments/RD%20Brochure%20022307.pdf (last visited: 22.02.10).
59. Reiß, T., Hüsing, B., Hinze, S., 1997. Indikatoren zur Bewertung von FuE-Strategien in der pharmazeutischen Industrie, Graue Reihe/Hans-Böckler-Stiftung, Hans-Böckler-Stiftung, Düsseldorf.
60. Rosenberg, N., 1990. Why do firms do basic research: (with their own money)? Research Policy 19 (2), 165-174.
61. Rosenberg, N., Nelson, R.R., 1994. American universities and technical advance in industry. Research Policy 23 (3), 323-348.
62. Rubenstein, A.H., 1989. Managing Technology in the Decentralized Firm. Wiley-Interscience, Wiley, New York.
63. Schoenecker, T., Swanson, L., 2002. Indicators of firm technological capability: Validity and performance implications. IEEE Transactions on Engineering Management 49 (1), 36-44. (Pubitemid 34295127)
64. Schumpeter, J.A., 1934. The Theory of Economic Development. Harvard University Press, Cambridge, MA.
65. Schumpeter, J., 1939. Business Cycles. McGraw-Hill Book Company, New York.
66. Sood, A., Tellis, G.J., 2005. Technological evolution and radical innovation. Journal of Marketing 69 (3), 152-168. (Pubitemid 41017933)
67. Sorescu, A.B., Chandy, R.K., Prabhu, J.C., 2003. Sources and financial consequences of radical innovation: Insights from pharmaceuticals. Journal of Marketing 67 (4), 82-102. (Pubitemid 37347412)
68. Stokes, D.E., 1997. Pasteur's Quadrant: Basic Science and Technological Innovation. Brookings Institution Press, Washington, DC.
69. Tanriverdi, H., Venkatraman, N., 2005. Knowledge relatedness and the performance of multibusiness firms. Strategic Management Journal 26 (2), 97-120.
70. Tijssen, R.J.W., 2004. Is the commercialisation of scientific research affecting the production of public knowledge?: Global trends in the output of corporate research articles. Research Policy 33 (5), 709-733.
71. Tijssen, R.J.W., Buter, R.K., van Leeuwen, T.N., 2000. Technological relevance of science: An assessment of citation linkages between patents and research papers. Scientometrics 47 (2), 389-412.
72. VFA, 2006. The pharmaceutical industry in Germany-Statistics 2006. Verband Forschender Arzneimittelhersteller e.V., http://www.vfa.de/download/ en/vfa en/publikationen en/e statistics/e statistics 2006.pdf (29.04.07).
73. Wernerfelt, B., Montgomery, C.A., 1988. Tobin's q and the importance of focus in firm performance. American Economic Review 78 (1), 246-250.
74. Wiklund, J., Shepherd, D., 2003. Knowledge-based resources, entrepreneurial orientation, and the performance of small and medium-sized businesses. Strategic Management Journal 24 (13), 1307-1314.
75. Zucker, L.G., Darby, M.R., 1997. Present at the biotechnological revolution: Transformation of technological identity for a large incumbent pharmaceutical firm. Research Policy 26 (4-5), 429-446. (Pubitemid 127401242)